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any other malignancy in the United States.2 Barrett’s
esophagus, a known complication of gastroesophageal
reflux disease, has been shown to give rise to adenocar-
cinoma of the distal esophagus and gastroesophageal
junction. This observation links one of the most deadly
malignancies known to mankind to the most common
upper gastrointestinal disorder in Western civilization.
Recognition of this relationship has resulted in an
increased detection of early esophageal cancers through
more prompt endoscopy of patients with reflux symp-
toms and the performance of surveillance endoscopy in
those with Barrett’s esophagus.
Management strategies for patients with early
esophageal cancers are evolving. In the past, our thera-
peutic strategy was based on treatment of patients with
squamous cell carcinomas, most of whom had advanced
T he past 2 decades have brought a dramatic change inthe epidemiology of esophageal cancer.1 Adeno-
carcinoma has replaced squamous cell carcinoma as the
most common esophageal malignancy, and the inci-
dence of adenocarcinoma has risen faster than that of
Objective: The purpose of this study was to characterize the prevalence
and location of regional lymph node metastases in adenocarcinoma con-
fined to the esophagal wall, to determine the extent of dissection
required, and to investigate the applicability of nonoperative therapy.
Methods: Histologic evaluation of the resected specimens after en bloc
esophagogastrectomy with mediastinal and abdominal lymphadenecto-
my was performed on 37 patients with adenocarcinoma confined to the
esophageal wall. Follow-up was complete in all patients (median 24
months). Results: Fifteen patients (41%) had intramucosal tumors.
Twelve (32%) had submucosal tumors and 10 (27%) had muscular inva-
sion. The prevalence of regional lymph node metastases (15/37 patients,
41%) increased progressively with depth of tumor invasion, with
involved nodes identified in 80% of patients with muscular invasion.
Lymph node metastases were also more common at distant node stations
in intramuscular tumors (5/10, 50%). Actuarial survival for the entire
group was 63% at 5 years. Recurrence was identified in 6 of the 37
patients (16%), with the risk of recurrence correlating with tumor
depth. Conclusions: Tumor depth is a strong predictor of the probabili-
ties of regional lymph node metastases, the likelihood of involvement of
distant node groups, and the risk of recurrence. Patients with invasion
of the muscular wall are at particularly high risk. En bloc esophagecto-
my with mediastinal and abdominal lymphadenectomy has the highest
likelihood of achieving an R0 resection. The long-term survival and low
recurrence rate achieved with an en bloc esophagectomy emphasizes the
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disease. As a result, Akiyama,3 Hagen,4 Altorki,5 and
their colleagues championed the application of the clas-
sic principles of surgical oncology in their therapy,
namely, complete resection of the primary tumor and
systematic lymph node dissection. The increasing preva-
lence of early adenocarcinoma has led to questioning of
the extent of operation required for cure in patients with
early disease and has led to the use of nonoperative ther-
apeutic techniques such as photodynamic therapy
(PDT). Before reductions in the extent of surgery or
alternative therapies are accepted, it is imperative that the
extent of disease in patients with early tumors be known.
It would be irrational for physicians or surgeons who
emphasize the importance of early detection as a major
factor in the cure of cancer to encourage therapy that
does not remove all of the disease present.
To characterize the extent of disease present in early
adenocarcinoma of the esophagus or gastroesophageal
junction, we reviewed our experience with en bloc
esophagogastrectomy and complete mediastinal and
abdominal lymphadenectomy in patients with tumors
limited to the esophageal wall. On the basis of the data
obtained, we sought to characterize the extent of dis-
section required to perform an R0 resection and to eval-
uate the applicability of nonoperative therapy, such as
PDT, for patients with early tumors.
Methods
The records of all patients who had an en bloc esophagec-
tomy for adenocarcinoma of the distal esophagus or gastroe-
sophageal junction from January 1, 1978, through February
1, 1998, were reviewed. The study population consisted of 37
patients whose primary tumor was confined to the esophageal
wall. The group comprised 31 men and 6 women, with a
median age of 59 years. A comparison group consisted of 28
patients with similar primary tumors who underwent transhi-
atal esophagectomy during the same period. This comparison
Fig 1. Algorithm depicting approach in patients with carcinoma of the esophagus, demonstrating selection of
operative technique. (From Hagen JA, DeMeester TR. En Bloc Esophagectomy for Cancer of the Distal
Oesophagus, Cardia and Proximal Stomach. In: Jamieson GG, Debas HT, editors. Surgery of the Upper
Gastrointestinal Tract. 5th ed. London: Chapman & Hall; 1994. p. 214-29. Published with permission.)
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was possible because the choice of operation in patients with
early tumors was based on co-morbidity. Those who were
under the age of 75 years and were free of significant cardiac
or pulmonary disease underwent en bloc esophagectomy,
whereas those who were older than 75 years or had signifi-
cant cardiac or pulmonary disease underwent transhiatal
resection. Patients were excluded from either group if they
had received preoperative chemotherapy or radiotherapy or
had undergone a previous esophageal or gastric resection.
Evaluation of the primary tumor. All patients had a bar-
ium roentgenogram and an endoscopic examination of the
upper gastrointestinal tract. Those with a visible tumor also
had a computed tomographic scan of the chest and abdomen
and endoscopic ultrasonography at 7.5 to 12 MHz.
Operative approach. All 37 patients in the study group
underwent an en bloc esophagogastrectomy with a systemat-
ic mediastinal and abdominal lymphadenectomy. The steps
for performing the procedure are shown in Fig 1.6 The oper-
ation begins with an exploration of the abdomen to assess the
extent of the primary tumor and the status of the regional
lymph nodes. In the absence of gross transmural tumor exten-
sion and multiple regional lymph node metastases or micro-
scopic involvement of the porta hepatis or subpancreatic
lymph nodes, the abdomen was closed and the patient was
prepared for a right thoracotomy.
An en bloc dissection was performed by resecting the azy-
gos vein, the thoracic duct, and the low paratracheal, subcari-
nal, paraesophageal, and parahiatal lymph nodes in continu-
ity with the esophagus. The block of tissue removed was
bounded laterally by the mediastinal pleura, anteriorly by the
membranous trachea and the pericardium, and posteriorly by
the spine and the aorta.
The abdominal dissection included removal of the proxi-
mal two thirds of the stomach, the greater omentum, the
spleen, the splenic artery along with its surrounding fibroare-
olar tissue, the nodes in the porta hepatis along the hepatic
artery, around the celiac axis, and the retroperitoneal lymph
node–bearing tissue. In most patients, gastrointestinal conti-
nuity was established by isoperistaltic colon interposition.
In the comparison group, a transhiatal esophagectomy was
performed according to previously described techniques.7
The operation included an abdominal lymph node dissection
similar to the en bloc operation, with the exception that the
spleen and splenic artery were not resected in the transhiatal
group. As many mediastinal lymph nodes were removed as
this approach would allow.
Analysis of the resected specimens. Two experienced
pathologists examined the resected specimens. The location
of the primary tumor was recorded. Tumors that were clearly
located in the tubular esophagus, above the gastric rugal
folds, were classified as being distal third esophageal can-
cers. The remaining tumors were classified as gastroesopha-
geal junction tumors. A detailed histologic evaluation was
performed to identify the depth of invasion of the primary
tumor and to search for areas of intestinal metaplasia
(Barrett’s mucosa) adjacent to the tumor. This was accom-
plished by sectioning the entire length of abnormal mucosa
longitudinally, in representative strips, with a 5-m m section
stained with hematoxylin and eosin for microscopic exami-
nation. All lymph nodes removed were identified according
to the lymph node stations shown in Fig 2. All lymph nodes
were formalin fixed and cut into two 5-m m sections for stain-
ing with hematoxylin and eosin. Local nodes were defined as
those in close proximity to the primary tumor, namely, the
parahiatal, lesser curvature, greater curvature, and left gastric
artery node groups.
Tumors that invaded the lamina propria but did not invade
past the muscularis mucosae were defined as intramucosal
cancers. Submucosal tumors included those that invaded
beyond the muscularis mucosae but not into the muscularis
propria. Tumors that invaded but did not penetrate through
the muscularis propria were classified as intramuscular
tumors.
Follow-up. The operating surgeon followed up all hospital
survivors at 3-month intervals for the first 3 years and every 6
months thereafter. The median duration of follow-up was 24
Fig 2. Lymph node staging map used to standardize node
locations.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 1
Nigro et al   19
months (range 3-203 months). Follow-up evaluation included
a history and physical examination, serum and liver chemistry
panels, a carcinoembryonic antigen level, and computed
tomographic scans of the chest and abdomen. All surviving
patients were either seen in person or contacted by telephone
within 3 months of the preparation of this manuscript.
Statistical analysis. Either c 2 or Fisher’s exact tests were
used for comparison of proportions. Continuous variables
were compared by means of the Mann-Whitney U test. Sur-
vival probabilities were calculated by the method of Kaplan
and Meier.8
Results
Extent of disease. The group was composed of 15
patients with tumors limited to the mucosa, 12 to the sub-
mucosa, and 10 to the muscularis propria. The tumor was
located at the gastroesophageal junction in 17 patients
(46%) and in the distal third of the esophagus in 20
(54%). Histologic evidence of Barrett’s esophagus was
found adjacent to the tumor in all but 2 patients (94.6%).
A total of 1631 lymph nodes were examined. The
median number of lymph nodes removed per patient after
systematic mediastinal and abdominal lymphadenectomy
was 41 (range 18-82). Involved lymph nodes were iden-
tified in 15 patients (41%). A comparison of the preva-
lence of regional lymph node metastases in tumors of var-
ious depths is shown in Table I. The frequency of nodal
metastases increased significantly with increasing tumor
depth, 80% of patients with intramuscular tumors having
involved nodes. The involved nodes in patients with
tumors limited to the mucosa and submucosa were con-
fined to the local node groups in all but 1 patient. In con-
trast, distant lymph nodes were involved in 5 of 10
patients with muscular invasion (c 2 = 11.8, P = .0027). In
addition to an increased frequency of involved regional
lymph nodes and their location at more distant sites,
patients with intramuscular tumors also tended to have a
greater number of involved nodes (Table I). Celiac node
metastases were present in 2 patients with intramuscular
tumors, and in both patients this was the only site of node
metastases. One of the patients died of systemic recur-
rence at 29 months, but the second is alive and free of
disease more than 2 years after resection. The number of
patients with involved lymph nodes and the locations of
the nodes are shown in Fig 3.
Table I. Lymph node prevalence and number in patients
undergoing en bloc esophagectomy 
Prevalence of No. of involved nodes 
Tumor depth involved nodes (median, range)
Intramucosal 1/15 (7%)* 0 (0-1)
Submucosal 6/12 (50%)* 0.5 (0-9)†
Intramuscular 8/10 (80%)* 1.0 (0-6)†
* c 2 = 14.05, P = .00089.
†P < .01 versus intramucosal group.
Fig 3. Relationship between the frequency of node involvement by node station and tumors of varying depths in
patients who had en bloc esophagectomy.
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Six patients had tumor recur during the follow-up
period. Three patients had node recurrence in the cer-
vical and paratracheal locations and 3 had distant organ
metastases. The likelihood of recurrence correlated
with both tumor depth and the presence of involved
lymph nodes (Fig 4). Five of 15 patients with involved
nodes had recurrence, compared with 1 of 22 patients
with uninvolved nodes. The median time to recurrence
was 24.5 months (range 19-86), and 4 of the 6 patients
have died of their recurrent disease. Two additional
patients have died of pneumonia and obstructing colon
cancer. Both were free of recurrent disease. Thus the
overall actuarial 5-year survival is 63%. In patients
who had an en bloc esophagogastrectomy with system-
atic mediastinal and abdominal lymphadenectomy, sur-
vival was not dependent on nodal status; 5-year sur-
vival in patients with involved nodes was 61%, which
was similar to the 56% survival in those without
involved nodes (P = .9, log rank test).
Type of resection and lymph node yield. The char-
acteristics of the comparison group of 28 patients who
underwent transhiatal esophagectomy were similar to
those of the 37 who underwent en bloc esophagectomy
(Table II). The location and depth of the tumors did not
differ significantly between the 2 groups. The median
number of nodes removed by transhiatal dissection was
significantly fewer than the number removed with an
en bloc dissection (14 vs 41, P < .0001). Involved
lymph nodes were identified in only 2 of the 28 patients
(7%) who underwent a transhiatal dissection. This was
significantly lower than the number of patients identi-
fied with involved nodes after an en bloc dissection
(2/28 vs 15/37, P = .0036). The relationship between
the depth of tumor invasion to the frequency of
involved nodes after an en bloc dissection was not
observed after a transhiatal dissection (Fig 5).
Difference between mucosal and submucosal T1
tumors. Twenty-seven patients had T1 tumors (15 with
intramucosal and 12 with submucosal invasion).
Fig 4. Relationship between the depth of tumor invasion and lymph node status and the likelihood of recurrence.
Table II. Comparison of patient characteristics
between patients treated by en bloc esophagectomy
and those treated by transhiatal resection
Comparison 
Study group group 
(n = 37) (n = 28) Significance
Sex (M/F) 31/6 23/5 P = 1.0
Age (y)* 59 (54-66) 72 (69-76) P < .0001
Cardia tumors 17 (46%) 17 (61%) P = .32
Depth
Intramucosal 15 (41%) 13 (46%) }P = .62Submucosal 12 (32%) 6 (21%)
Intramuscular 10 (27%) 9 (32%)
Nodes removed* 41 (34-53) 14 (4-27) P < .0001
Patients with 15 (41%) 2 (7%) P = .0036
positive nodes
Operative mortality 2 (5.4%) 2 (7.1%) P = 1.0
Study group = en bloc esophagectomy; comparison group = transhiatal
esophagectomy. 
*Values expressed as median (interquartile range).
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Twelve had an endoscopically visible lesion and 15 did
not. Endoscopic ultrasonography in those with visible
lesions could not accurately differentiate between intra-
mucosal and submucosal tumors. Tumors limited by
the muscularis mucosae had only a 7% prevalence of
nodal involvement, whereas tumor extension across the
muscularis mucosae into the submucosa resulted in a
50% prevalence of involved nodes (Table I).
Discussion
Over the past 2 decades the frequency of adenocarci-
noma of the esophagus has arisen to the point that it has
now surpassed squamous cell cancer as the most com-
mon cell type. Recognition of the association between
gastroesophageal reflux and esophageal adenocarcino-
ma has led to more prompt endoscopy in patients with
refractory reflux symptoms and the institution of sur-
veillance protocols for those with evidence of Barrett’s
esophagus. This has led to an increasingly larger group
of patients being referred for treatment with an early-
stage esophageal cancer.
These patients represent a dilemma in that our current
treatment strategies are based on experience with more
advanced disease, observations that may not be valid in
patients with early-stage tumors confined to the
esophageal wall. This has led to the recommendation of
less aggressive surgery for patients with early tumors
and even the proposal that nonoperative treatment
options are appropriate.9-11
The value of a complete (R0) resection as a predictor
of long-term survival has been repeatedly shown.12-14
For the extent of resection necessary to achieve R0 status
to be clarified, both the frequency and the location of
involved lymph nodes must be appreciated. This can be
accomplished only through an experience such as that
reported here, with systematic resection of all potential-
ly involved regional lymph nodes. In our experience,
93% of patients with tumors limited to the mucosa are
free of regional lymph node metastases. Once the tumor
penetrates the muscularis mucosa, 50% of the patients
have involved lymph nodes. Even though nearly all of
these nodes are confined to local node groups, their
removal becomes a chance phenomenon with a transhi-
atal dissection (Figs 3 and 5). When the tumor invades
the muscularis propria, 80% of the patients will have
regional lymph node metastases, with the involved nodes
commonly in locations beyond the confines of a transhi-
atal dissection. The limitations of our preoperative stag-
ing techniques for an endoscopically visible tumor pro-
hibit the accurate differentiation between those that are
limited to the mucosa, extend into the submucosa, or
invade the muscularis propria.15 Consequently, to confi-
dently achieve an R0 resection of an endoscopically vis-
ible tumor requires an en bloc resection with a systematic
mediastinal and abdominal lymphadenectomy. This con-
clusion is supported by our finding that the prevalence of
node metastases is dependent on the extent of dissection.
Patients with the compromised mediastinal lymph node
dissection predicated by the transhiatal approach have
fewer involved nodes, and the relationship between
tumor depth and node status is lost. To explain this
observation, either our selection process would have
favored patients with less advanced disease for transhi-
atal resection or involved nodes were left behind. The
latter seems more likely in that the distribution of tumors
of various depths was similar in those who had an en
Fig 5. Relationship between depth of tumor invasion and the frequency of involved lymph nodes after en bloc and
transhiatal esophagectomy.
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bloc or transhiatal dissection (Table II); therefore it is
likely that the nodal involvement would be similar.
Furthermore, we have previously shown the superiority of
an en bloc esophagectomy4 in patients with early
esophageal cancer, an outcome one would expect if the
transhiatal dissection left involved lymph nodes behind.
Rice and associates16 have reported a similar relation-
ship between tumor depth and lymph node metastases
after transthoracic esophagectomy, although the absolute
values for the prevalence of node metastases in their
series was slightly lower than that which we have report-
ed. Just as we have observed, these authors have demon-
strated a clear relationship between the completeness of
node dissection and the likelihood of involved nodes.
Their series differed from ours in that they included both
adenocarcinoma and squamous cell cancers, and the
magnitude of the operation and lymph node dissection
was less. Both their findings and ours indicate that to
achieve an R0 resection with confidence in patients with
endoscopically visible tumors confined to the esopha-
geal wall requires an en bloc resection with a systematic
mediastinal and abdominal lymphadenectomy.
The depth of tumor penetration into the esophageal
wall and the frequency of nodal metastases becomes
critically important when considering alternatives to
resection, such as PDT. Nodal metastases, if present,
would remain untreated by this and other strategies that
focus only on ablation or removal of the mucosa. In
patients with tumors limited to the mucosa, PDT and
endoscopic mucosal resection can achieve survival in
excess of 90%.17,18 Recently, patients with T1 tumors
(including both intramucosal and submucosal tumors)
have been proposed as candidates for these types of
nonoperative therapy. We have shown that 50% of T1
tumors that extend into the submucosa will have evi-
dence of lymph node metastases when a complete node
dissection is performed. Although intramucosal tumors
might be considered for such an approach, given the
very low incidence of involved nodes in this subgroup,
problems exist in accurately identifying patients with
tumors limited to the mucosa with presently available
techniques. Endoscopic ultrasonography, while accu-
rately identifying T3 and T4 tumors, is much less accu-
rate in differentiating between T1 and T2 tumors and is
incapable of subclassifying T1 tumors into intramucos-
al and submucosal subgroups.15,19 Advocating nonop-
erative therapy for patients with T1 tumors exposes a
number of them to the risk of incomplete destruction of
their primary tumor and the persistence of involved
lymph nodes. Compromising the benefit of early detec-
tion in curing this lethal disease needs to be seriously
weighed against the benefits of avoiding a surgical pro-
cedure by technical advances that risk incomplete
removal of the tumor.
In 3 of the 6 patients with tumor recurrence during fol-
low-up, the recurrence was in the paratracheal and cer-
vical lymph nodes. This fact could be used as an argu-
ment for extending the dissection to include these node
groups (so-called 3-field dissection). To date, however,
we have not used this technique in patients with early
adenocarcinoma of the esophagus. Whether the potential
benefit of the extended resection is worth the associated
increased morbidity in patients with tumors limited to
the esophageal wall (only 8% of whom have recurrence
in those node groups) remains to be proven.
The final question to be addressed is whether an R0
resection has a survival benefit in patients with early
disease. To answer this question formally would re-
quire a randomized prospective trial, but some infer-
ences are possible on the basis of the experience report-
ed here. The long-term survival of 61% after en bloc
resection in patients with tumors confined to the
esophageal wall and lymph node metastases would
argue strongly that an R0 resection was beneficial for
their survival. Our long-term survival in the setting of
involved nodes is impressive when compared with the
survival data recently reported by Sabik and associ-
ates20; in their series no patients with involved nodes
survived long term. If the benefit of an R0 resection is
accepted, then our observation that transhiatal resection
leaves residual disease untreated strongly supports the
need for a more complete nodal dissection in patients
with early disease.
Conclusions
Tumor depth is a strong predictor of the probability
of lymph node metastases, the likelihood of involve-
ment of distant nodes, and the risk of recurrent disease.
Patients with invasion of the muscular wall are at par-
ticularly high risk. En bloc esophagectomy with medi-
astinal and abdominal lymphadenectomy has the high-
est likelihood of achieving an R0 resection in these
patients. The long-term survival and low recurrence
rate achieved with this operation emphasize the impor-
tance of an aggressive surgical approach that includes
removal of all potentially involved nodes. These find-
ings, as well as the inability to differentiate tumors lim-
ited to the mucosa from those that penetrate deeper,
discourages the use of nonoperative therapy.
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Discussion
Dr Thomas W. Rice (Cleveland, Ohio). The presence of
lymphatic vessels in the esophageal mucosa makes it unique
among gastrointestinal hollow viscus organs. Mucosal and
submucosal lymphatics form a complex interconnecting net-
work that extends the length of the esophagus and exceeds
capillaries in numbers. Intermittently, these lymphatics pierce
the muscularis propria and drain into regional lymph nodes
and, in some patients, directly into the thoracic duct. This
lymphatic anatomy allows early and widespread dissemina-
tion of esophageal carcinoma. 
As soon as a carcinoma breaches the basement membrane
and invades the lamina propria, it encounters lymphatics.
With deeper invasion, there is an increasing exposure to lym-
phatics and a potential for extensive longitudinal submucosal
lymphatic extension and lateral metastases to regional lymph
nodes and systemic lymphatics. 
We have recently reported our experience with 359 con-
secutive patients undergoing esophageal resection only for
esophageal carcinoma. The survival of patients with regional
lymph node metastases was 7% at 5 years. We agree with Dr
Hagen and his colleagues that depth of tumor invasion is the
best predictor of regional lymph node metastases. Compared
with a patient with T1 disease, a patient with T2 disease is 6
times more likely to have N1 disease, a patient with T3 dis-
ease 23 times, and a patient with T4 disease 34 times. 
It is crucial for pathologic staging and therapy that a com-
plete lymphadenectomy and analysis of all resected lymph
nodes be done. I have 2 questions and 1 comment.
First, Dr Hagen, could you please elaborate on the patho-
logic analysis of resected nodes, and were any special stains
used to enhance the detection of metastases? 
Second, in the best surgical candidates, you chose en bloc
esophagectomy, lymphadenectomy, and colon interposition;
in poor-risk candidates, you used a transhiatal esophagectomy.
The mortality rates in these 2 dissimilar groups were very sim-
ilar. Could you comment on the morbidity and mortality asso-
ciated with en bloc esophagectomy and colon interposition? 
Finally, I believe this work is an important message to all
physicians who treat esophageal carcinoma. The benefit of
surveillance for early-stage disease will be lost in the patient
with carcinoma limited to the esophageal wall if therapeutic
modalities provide incomplete ablation of the cancer.
Esophagectomy with lymphadenectomy is the gold standard
against which all other forms of treatment must be measured. 
Dr Hagen. Thank you, Dr Rice, for your comments and
questions. With regard to the pathologic analysis, we removed
1631 lymph nodes in these 37 patients. In this particular report
we are dealing only with routine pathologic assessment of the
lymph nodes by standard staining techniques. We have been
looking recently at immunohistochemical studies done on
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lymph nodes, focusing specifically on patients who otherwise
have N0 disease. Although a number of reports have appeared
in the literature assessing the value of immunohistochemical
staining of lymph nodes, most of these studies have been on
uninvolved nodes in patients who have nodal disease else-
where. It is hard to know exactly what that means. 
In a study currently in progress, involving a series of
patients who had no evidence of lymph node involvement
after complete lymph node dissection, thus far about 20%
have immunohistochemical evidence of lymph node metas-
tases. Although we know the number of patients with
involved nodes, on immunohistochemistry, what we do not
know is what this means in terms of prognosis. 
With regard to the mortality and morbidity after the en bloc
esophagectomy, the mortality in this series was about 5%,
which is the same as the mortality rate for patients with more
advanced tumors, but is about twice the mortality rate in
esophagectomy and colon interposition for benign disease.
The morbidity, however, is substantial, with 30% to 40% hav-
ing some sort of complication that extends their hospital dis-
charge. The average period of hospitalization in this series
was about 14 days, which is longer than is typically seen after
transhiatal esophagectomy. Nonetheless, most of these com-
plications can be dealt with quite readily and rarely translate
into mortality. As a result, if patient survival can be enhanced,
I believe that the additional morbidity of an en bloc esopha-
gectomy is worth risking.
Dr Mark J. Krasna (Baltimore, Md). I agree with both Dr
Hagen and Dr Rice on the importance of lymph node staging
in esophageal cancer. I would like to emphasize the location
of the lymph nodes. Of interest is that some of the previous
works by Akiyama, Sugarbaker, and Altorki (at last year’s
meeting of this Association) have shown a higher incidence
of distant metastatic disease to lymph nodes than you report-
ed this morning. This is an area that we must concentrate on,
especially in light of some of the recent reports, including
that by Dr Rice, of using combined modality therapy. 
At our institution we have recently published a series of 39
patients in whom, using preresection lymph node staging, we
were able to target distant lymph node spread that was other-
wise undetected in 20% to 30% of the patients and target our
radiation therapy field to a much higher level than we otherwise
would have done in a trimodality protocol. Will you please
comment on the importance of distant metastatic disease and
where you think these patients will fit in the overall plan?
Dr Hagen. Thank you, Dr Krasna, for your questions. 
We identified only 6 patients with tumors confined to the
esophageal wall with distant nodal involvement. Because the
numbers are so small, it is hard to make any comparisons
about whether that extent of tumor has any effect on recur-
rence. It is my sense, though, that all potentially involved
nodes should be removed. This is based on the published evi-
dence in a number of cancers, esophageal cancer included,
which shows that one of the most important prognostic fac-
tors is achieving a complete (R0) resection. It is very hard to
argue that if you do not remove all of the disease that may be
present, at least if the only treatment is going to be surgery,
you have accomplished curative therapy.
With respect to even more widespread lymph node disease,
disease that might spread to the neck or the upper part of the
chest, a number of people are investigating the so-called 3-
field lymph node dissection. We have not chosen to do that,
particularly in these patients with early cancer, for 2 reasons:
First, these patients with very early cancers must have a van-
ishingly small number of nodes all the way up in the neck.
We have decided that the additional morbidity is not warrant-
ed, given the small number who would be expected to bene-
fit. Second, it is not clear, just what these nodes mean, that is,
whether they represent local regional disease or whether they
are more characteristic of metastatic disease. The American
Joint Committee on Cancer Staging currently classifies these
cervical nodes as metastatic disease, and I suspect that that is
probably the way they should be viewed. If that is the case,
then it is hard for me to accept an approach that involves sur-
gical treatment for what appears to be systemic disease.
Dr Thomas M. Egan (Chapel Hill, NC).Your patients who
underwent transhiatal esophagectomy had co-morbidities that
might lead you to expect them to have a more adverse out-
come in the long term. Can you share with us what the actu-
arial 1- and 2-year survivals were for your patients who had
transhiatal esophagectomy as opposed to patients who had
complete esophagectomy and colon interposition? 
Dr Hagen. Thank you, Dr. Egan. The survival after transhi-
atal esophagectomy in this group was similar but slightly
lower; it was about 15% lower overall at 2 years, when com-
pared with en bloc resection. As I mentioned, 2 patients died of
non-cancer-related causes in the en bloc group and 3 patients
in the transhiatal group. As a result, although the patients are
selected for operation on the basis of co-morbidity, the major-
ity of patients in both series who died, did die with recurrent
disease. 
Dr Egan. But isn’t the bottom line not how many lymph
nodes you take out but how many survivors you have? 
Dr Hagen. Yes. In this report we have a series that compares
37 patients after en bloc resection with 28 patients who under-
went transhiatal esophagectomy. These are obviously small
numbers. The ability of a study of this size to detect modest
differences in survival is thus limited. In fact, that is precisely
why we chose not to analyze survival. However, if we had
reported a series of 100 or 200 patients, with a similar differ-
ence in survival, the 15% difference in survival would be sig-
nificant. Obviously, such questions about the power of the
study and speculation about the possibility of type II error are
difficult. The major point is that it is very hard to make an argu-
ment that an operation that admittedly does not remove all of
the disease that is present is, in itself, adequate treatment for
the disease. 
Dr Nasser K. Altorki (New York, NY). We showed a year
ago that the mortality and the morbidity of radical resections
are comparable with those of standard transthoracic resec-
tions. We have also shown that the staging in terms of the
number of nodes per patient is higher in the radical resections
than in the standard transthoracic resections. Now you have
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extended that to the transhiatal resections, and I think both of
those observations are correct. 
I am puzzled as to the reason for your continued selectivity
in choosing 1 operation versus the other. We decided 6 or 7
years ago that we would pursue 1 approach rather than be
selective to have a meaningful interpretation of the data; oth-
erwise, one cannot escape that some patients are selected for
a lesser operation. 
My question relates to the depth of tumor invasion. We have
performed nearly 60 3-field lymph node dissections for
esophageal cancer, now almost a routine operation for us. I
agree with you that submucosal cancers are not early cancers,
they are advanced cancers, and the only issue here is how to
select the intramucosal carcinomas, because those could con-
ceivably be treated either nonoperatively or by a transhiatal
resection.
How do you go about doing that selection? Do you use any
modalities like endoscopic ultrasonography?
Dr. Hagen. Thank you, Dr. Altorki. This series represents a
number of patients accumulated over about a 10-year period,
and during that time period we have made the same observa-
tion that you have, that there does not appear to be as much
difference, at least from the mortality standpoint, between the
transhiatal and the en bloc esophagectomy. I do think the
morbidity is a little higher with en bloc esophagectomy, but
not alarmingly so. That has led to our being less selective in
terms of the types of patients in whom we have done en bloc
esophagectomy in more recent years. 
With regard to the means of selecting these patients, I
agree, if there was a way to identify with precision patients
who had only mucosal disease, who had a very low incidence
of nodal metastases, much less aggressive treatment could be
offered to them. In fact, one might even argue that, since only
1 patient had a single diseased node, it might be possible to
treat the mucosa alone by ablation techniques. The gastroen-
terologists would love that sort of conclusion. The problem
is, we cannot do that right now. We do not have an accurate
way to reliably differentiate between mucosal and submucos-
al tumors, and invasion of the submucosa is always a sign of
significant locoregional disease. 
One factor that we have recently identified as a means of
identifying patients with very early tumors, likely confined to
the mucosa, is the presence or absence of a visible lesion.
Patients who have biopsy-proven cancer with no endoscopi-
cally visible mass, identified in the course of surveillance, are
very likely to have mucosal disease. If the tumor does get into
the submucosa, it is very early invasion, and the likelihood of
lymph nodes being involved is quite low.
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